Mental Health Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT), Universitat Autònoma de Barcelona (UAB), Biomedical Research Networking Center Consortium on Mental Health (CIBERSAM), Parc Taulí 1, 08208 Sabadell, Catalonia, Spain.
Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), Biomedical Research Networking Center Consortium on Mental Health (CIBERSAM), Sant Antoni Mª Claret 167, 08025 Barcelona, Catalonia, Spain.
Psychol Med. 2021 Dec;51(16):2886-2894. doi: 10.1017/S0033291720001567. Epub 2020 Jun 1.
Heterogeneity in cognitive functioning among major depressive disorder (MDD) patients could have been the reason for the small-to-moderate differences reported so far when it is compared to other psychiatric conditions or to healthy controls. Additionally, most of these studies did not take into account clinical and sociodemographic characteristics that could have played a relevant role in cognitive variability. This study aims to identify empirical clusters based on cognitive, clinical and sociodemographic variables in a sample of acute MDD patients.
In a sample of 174 patients with an acute depressive episode, a two-step clustering analysis was applied considering potentially relevant cognitive, clinical and sociodemographic variables as indicators for grouping.
Treatment resistance was the most important factor for clustering, closely followed by cognitive performance. Three empirical subgroups were obtained: cluster 1 was characterized by a sample of non-resistant patients with preserved cognitive functioning ( = 68, 39%); cluster 2 was formed by treatment-resistant patients with selective cognitive deficits ( = 66, 38%) and cluster 3 consisted of resistant ( = 23, 58%) and non-resistant ( = 17, 42%) acute patients with significant deficits in all neurocognitive domains ( = 40, 23%).
The findings provide evidence upon the existence of cognitive heterogeneity across patients in an acute depressive episode. Therefore, assessing cognition becomes an evident necessity for all patients diagnosed with MDD, and although treatment resistant is associated with greater cognitive dysfunction, non-resistant patients can also show significant cognitive deficits. By targeting not only mood but also cognition, patients are more likely to achieve full recovery and prevent new relapses.
重度抑郁症(MDD)患者的认知功能存在异质性,这可能是迄今为止与其他精神疾病或健康对照组相比,报道的差异较小的原因。此外,这些研究大多没有考虑到可能对认知变异性起重要作用的临床和社会人口学特征。本研究旨在根据急性 MDD 患者的认知、临床和社会人口学变量确定实证聚类。
在 174 名急性抑郁发作患者的样本中,应用两步聚类分析,将潜在相关的认知、临床和社会人口学变量作为分组指标。
治疗抵抗是聚类的最重要因素,其次是认知表现。得到了三个经验性亚组:第 1 组由非耐药、认知功能正常的患者组成(n=68,39%);第 2 组由治疗耐药、选择性认知缺陷的患者组成(n=66,38%);第 3 组由耐药(n=23,58%)和非耐药(n=17,42%)急性患者组成,所有神经认知域均存在显著缺陷(n=40,23%)。
研究结果表明,在急性抑郁发作患者中存在认知异质性。因此,评估认知对所有被诊断为 MDD 的患者来说都是必要的,尽管治疗耐药与更大的认知功能障碍相关,但非耐药患者也可能表现出明显的认知缺陷。通过不仅针对情绪,还针对认知,患者更有可能实现完全康复并预防新的复发。